Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next.
Updated: November 8, 2025
Top takeaways
- Pfizer wins the bidding war: Metsera accepted Pfizer’s sweetened offer valuing the company at up to $86.25 per share ($65.60 cash + up to $20.65 via CVR). [Reuters]
- Novo Nordisk exits: Novo said today it will not raise its proposal and is stepping aside. [GlobeNewswire]
- Shareholder vote next week: Metsera is slated to hold its special meeting on November 13, 2025, with both companies expecting a prompt close if approved. [Reuters]
- Why it matters: The deal gives Pfizer a faster route back into the booming anti-obesity market and locks up Metsera’s GLP-1 and amylin programs that some analysts see hitting multi-billion-dollar peak sales. [Reuters]
What changed on Nov. 7–8
Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing structure after a call from the U.S. FTC. [PR Newswire] https://www.prnewswire.com/news-releases/p…
Saturday, Nov. 8: Pfizer was widely reported as the winner of the ~$10 billion contest as Novo confirmed it won’t raise its bid. Coverage also reiterated the revised price and expectation of closing soon after Metsera’s Nov. 13 vote. [Reuters] https://www.reuters.com/business/healthcar…
Deal terms at a glance
- Total consideration: Up to $86.25 per Metsera share: $65.60 cash plus a CVR of up to $20.65 cash. [PR Newswire]
- Rationale for board support: Higher closing certainty versus Novo’s alternative and lower legal/regulatory risk after FTC outreach regarding Novo’s structure. [PR Newswire]
- Next milestone: Special shareholder meeting on Nov. 13, 2025; both sides indicate prompt close if approved and conditions are satisfied. [Reuters]
Novo Nordisk’s position today
Novo Nordisk stated this morning it will not increase its proposal after previously submitting unsolicited, revised offers during the week. The company said its structure complied with antitrust law but it is maintaining financial discipline and stepping back from the Metsera pursuit. [GlobeNewswire]
Why Metsera matters in the weight-loss race
Metsera is developing next-generation anti-obesity candidates, including MET-097i (a GLP-1 injectable) and MET-233i (an amylin analog). Analysts estimate the company’s obesity portfolio could eventually reach around $5 billion in combined peak sales — an expectation that helped fuel the competitive bidding and underscores why Pfizer moved to secure the assets. [Reuters]
How the market is reacting
Metsera shares have surged during the week of headlines. From just before Novo entered the fray to Friday’s close, MTSR rose nearly 60%, reflecting optimism around improved economics and deal certainty. [Reuters]
What happens to MTSR if the deal closes?
- Cash payout: Holders would receive $65.60 per share in cash at closing, subject to the terms of the merger agreement. [PR Newswire]
- CVR upside: Investors would retain a contingent value right (CVR) that may pay up to $20.65 per share if specified clinical/regulatory milestones are achieved on Metsera’s programs post-close. (CVR payments are not guaranteed.) [PR Newswire]
- Trading status: If approved and closed, Metsera would cease to trade as an independent public company, with timing guided by next week’s vote and standard closing conditions. [Reuters]
Key dates and documents
- Nov. 7, 2025: Metsera and Pfizer amended their merger agreement; board reaffirmed support. [PR Newswire]
- Nov. 8, 2025: News outlets report Pfizer as the winner as Novo confirms it won’t raise its bid. [Reuters]
- Nov. 13, 2025: Metsera special meeting of stockholders to vote on the amended Pfizer transaction. [Reuters]
Why Pfizer’s win matters beyond Metsera
The agreement gives Pfizer a direct pipeline foothold in obesity after prior in-house setbacks, positioning it to challenge incumbents as GLP-1 and related mechanisms expand into broader metabolic and cardiometabolic indications. For Novo Nordisk, the outcome avoids heightened antitrust scrutiny and preserves capital for internal pipeline and other business-development opportunities. [Reuters]
Editor’s note: This story reflects developments published on November 7–8, 2025, including Metsera’s amended merger agreement with Pfizer, Novo Nordisk’s withdrawal, and widely reported expectations for a prompt close following the Nov. 13 vote. For investors and readers who want the primary sources, see the amended-merger announcement from Metsera, Novo Nordisk’s statement, and today’s coverage in Reuters and Bloomberg.
Disclosure: This article is for informational purposes only and does not constitute investment advice. Always read company filings and consult a qualified adviser before making financial decisions.
